GOECP

2.6K posts

GOECP banner
GOECP

GOECP

@goecp1

Twitter oficial del Grupo Oncológico para el Estudio del Cáncer de Pulmón. #lcsm #radonc

Spain Katılım Haziran 2019
117 Takip Edilen535 Takipçiler
GOECP retweetledi
Eric K. Singhi, MD
Eric K. Singhi, MD@lungoncdoc·
#NORTHSTAR update #ELCC26 1️⃣Post-osi CT @ 6-12 wks •Nodes cleared: 41.5 v 19.6 mo •Persistent: no benefit •Effusion gone: 32.7 v 22.3 mo •Persistent: no benefit 2️⃣RT w/ strong local control •8% in v 92% out-of-field 3️⃣RT technique •BED≥75:⬆️outcomes •V20<25%:⬇️toxicity
Eric K. Singhi, MD tweet mediaEric K. Singhi, MD tweet media
Hidehito HORINOUCHI@HHorinouchi

🆙 #ELCC26 @myESMO @IASLC 🇩🇰 🔥Mini Oral session 1 ☑️NorthStar 🎯PFS Osi +/- LCT 41.5m vs. 19.6m (HR 0.43, 90%CI 0.23–0.78) 🎙️Dr. Saumil Ghandi 🎙️Chair: @DocSacher Dr. Andreas Rimner 📍NCT04479306 @OncoAlert @Larvol #LCSM

English
1
12
24
3.3K
GOECP retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
🔥 ELCC26 Day 2 Recap - Practice Signals Getting Sharper #ELCC26 🧬 ASTEROID Trial SBRT ± Durvalumab (early-stage inoperable NSCLC) 👉 SBRT → durvalumab vs SBRT alone 📈 TTP signal (p=0.054) ❌ No DFS / OS benefit ⚠️ Mostly G1–2 toxicity ➡️ Not practice-changing yet 🧬 NorthStar Trial (LBA3) LCT + Osimertinib 👉 EGFRm mNSCLC post-induction osi 🔥 PFS: 25.4 vs 17.5 mo (HR 0.66) 🎯 Best benefit: ✔️ No residual nodal disease ✔️ No pleural effusion ❌ No benefit if residual disease persists ➡️ Patient selection is everything 🧬 BECOME Trial (Phase II) EGFR exon 20ins 👉 Becotrag + Osimertinib 🔥 mOS: 18.0 mo 📊 Far-loop > Near-loop (HR 0.58) 🧬 ctDNA (-) → OS 36.6 mo vs 19.2 mo ➡️ Biology > response in predicting survival 🧬 ETOP ADEPPT Trial (Phase II) Adagrasib in elderly/PS2 👉 KRAS G12C+ NSCLC ✔️ Fit elderly (PS 0–1): meaningful activity ❌ PS2: limited benefit, higher toxicity ⚠️ 1 fatal TRAE ➡️ Use selectively, not for frail @OncoAlert @myesmo @esmo_open @asco @larvol #LungCancer #NSCLC #SCLC
Dr Rishabh Jain tweet mediaDr Rishabh Jain tweet mediaDr Rishabh Jain tweet mediaDr Rishabh Jain tweet media
English
2
10
19
1.5K
GOECP retweetledi
OncoAlert
OncoAlert@OncoAlert·
The #OncoAlertColloquium 2026 Thoracic Malignancies🚨 #ELCC26 Presentation by Dr. Gilberto Lopes🇺🇸 : Year in Review Early #NSCLC WATCH NOW, NO REGISTRATION👉 buff.ly/hqSd5tp Practice-changing research in 2025 in early NSCLC 🚀 ✔️ Clearer insights on neoadjuvant vs adjuvant immunotherapy + chemo, with growing OS benefit ✔️ Alectinib & osimertinib now firmly established as adjuvant standards ✔️ SBRT validated for selected small stage I tumors ✔️ RiskReveal enables genomic risk stratification in early-stage disease 🧬 🔑 Take-home: early NSCLC is moving fast toward precision, personalization, and de-escalation where appropriate. #LungCancer @GlopesMd🇺🇸 @jillfeldman4 @EGFRResisters🇺🇸 @UmbertoMalapel1 🇮🇹 @isliquidbiopsy @BRicciutiMD 🇺🇸 @UOzkerim 🇹🇷 @gerryhanna @ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg @acampsmalea @HHorinouchi @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago @matteolambe @Icro_Meattini @GlopesMd @NarjustFlorezMD @StephenVLiu @JackWestMD @bmassutis @peters_solange @christine_lovly @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo @MartinReck2 @Latinamd @JulienMazieres @nataliagandur
English
0
10
14
1.7K
GOECP retweetledi
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🆙 #ELCC26 @myESMO @IASLC 🇩🇰 🔥Mini Oral session 1 ☑️ASTEROID: SBRT +/- Durvalumab 🎯Time to progression was significantly improved by durvalumab 🎙️Dr. Andreas Hallqvist 🎙️Chair: @DocSacher Dr. Andreas Rimner 📍NCT03446547 @OncoAlert @Larvol #LCSM
Hidehito HORINOUCHI tweet mediaHidehito HORINOUCHI tweet mediaHidehito HORINOUCHI tweet mediaHidehito HORINOUCHI tweet media
Hidehito HORINOUCHI@HHorinouchi

🆙 #ELCC26 @myESMO 🇩🇰 🔥Mini Oral session 1 ☑️ASTEROID: SBRT +/- Durvalumab 🎯Time to progression was significantly improved by durvalumab 🎙️Dr. Andreas Hallqvist 🎙️Chair: @DocSacher Dr. Andreas Rimner 📍NCT03446547 @OncoAlert @Larvol #LCSM

English
1
6
11
1.7K
GOECP retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
🚨 Day 3 #ELCC26 – Trials to Watch 🫁 Early-stage NSCLC – perioperative IO maturity 🔹 KEYNOTE-671 (222MO, 223MO) 5-year outcomes by pCR vs non-pCR 👉 Long-term validation of perioperative pembrolizumab 🎯 EGFR-mut NSCLC – post-TKI evolution 🔹 OptiTROP-Lung03 (LBA4) Sacituzumab tirumotecan in pretreated EGFRm NSCLC 👉 ADCs entering EGFR-resistant space 🔹 TQB2922 (9MO) EGFR/MET bispecific ± combinations 👉 Targeting dual resistance pathways 💥 HER3 ADC wave expands 🔹 SHR-A2009 + aumolertinib (10MO) 🔹 YL202/BNT326 (11MO) 👉 HER3 emerging as next big target in NSCLC 🧪 IO resistance & rechallenge strategies 🔹 LATIFY (LBA1) Ceralasertib + durvalumab post IO + chemo 👉 DDR targeting to overcome IO resistance 🔹 i-TIMES (LBA2) Optimal timing of immunotherapy 👉 Sequencing may matter more than we think 🧬 Squamous NSCLC post-IO 🔹 PRESERVE-003 (3O) Gotistobart vs docetaxel 👉 New options beyond chemo in IO-pretreated setting 📊 Screening & real-world impact 🔹 LBA5 Low-dose CT screening in non–risk-based population 👉 Potential paradigm shift beyond high-risk cohorts #ELCC26 #LungCancer #NSCLC #ThoracicOncology @OncoAlert @myesmo @esmo_open @asco @Larvol
Dr Rishabh Jain tweet media
Dr Rishabh Jain@DrRishabhOnco

🚀 #ELCC26: 7 Thoracic Oncology Trials That Could Shift NSCLC Practice Thoracic oncology is clearly moving toward ADCs, resistance biology, and smarter IO strategies. Here are the trials that matter 👇 🧬 Beamion LUNG-1 (Zongertinib) A serious T-DXd challenger in HER2-mutant NSCLC → Strong focus on CNS activity + durability signals 🎯 BL-B01D1-204-01 (Bispecific ADC) EGFR/HER axis targeting beyond TKIs → Key strategy for post-TKI resistance ⚡ 3082-CL-0101 (ADC platform) Next-gen ADC sequencing question → Watch ILD signals + positioning in treatment flow 🛡️ KEYNOTE-671 (Perioperative Pembrolizumab) Already practice-influencing → OS maturity could firmly establish periop IO standard 🔬 TOP (Next-gen IO strategy) Beyond chemo-IO plateau → Selection vs intensification dilemma 🧠 ASTEROID & BECOME Resistance-focused trials → PD-L1 low + primary/secondary resistance solutions 💡 Takeaway: We are entering the post-chemo-IO era → ADCs + precision IO will define next-line standards 🔖 Save this for ELCC26 updates 📖 Full insights + visuals coming soon #OncoTwitter #LungCancer #NSCLC #ThoracicOncology @OncoAlert @myesmo @esmo_open @asco @Larvol

English
1
10
21
16.2K
GOECP retweetledi
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
Not all EGFR NSCLC is the same… TP53 co-mutation changes the game #ELCC26 Phase 3 TOP trial 🧬 EGFR + TP53 mutated advanced NSCLC ⚔️ Strategy tested 🟢 Osimertinib + chemo 🟠 Osimertinib alone 📊 Signal is hard to ignore • PFS: 34.0 vs 15.6 mo → HR 0.44 • OS (immature): 48.4 vs 36.5 mo → HR 0.57 🛡️ Toxicity Expected chemo-related ↑ modifications, no new safety flags 💡 Clinical thought TP53 co-mut = biologically aggressive EGFR disease 👉 upfront chemo + TKI may be the better default 📖 Full paper awaited ⬇️ #LungCancer #OncoTwitter @OncoAlert @myesmo @esmo_open @ASCO @larvol
Dr Rishabh Jain tweet mediaDr Rishabh Jain tweet mediaDr Rishabh Jain tweet mediaDr Rishabh Jain tweet media
Dr Rishabh Jain@DrRishabhOnco

🚨 TP53 + EGFRm NSCLC - upfront intensification wins #ELCC26 🧪 TOP Trial (Phase III) Osi ± chemo in EGFRm + TP53 co-mutation ⚔️ Arms 🟢 Osi + chemo 🔵 Osi 📊 Key results 🔥 PFS: 34.0 vs 15.6 mo (HR 0.44, p<0.001) 📈 ORR: 82.9% vs 72.0% ⏳ DoR: 32.7 vs 15.3 mo 🧠 Benefit in CNS mets ⚠️ Grade ≥3 AEs: 62.4% vs 14.9% ⏳ OS: immature (HR 0.57) 💡 Takeaway 👉 TP53 co-mut = high-risk EGFR NSCLC 👉 Osi + chemo may become preferred 1L approach #OncoTwitter #MedTwitter #LungCancer #NSCLC #EGFR @OncoAlert @myesmo @esmo_open @ASCO

English
0
20
41
5.9K
GOECP retweetledi
JAMA Oncology
JAMA Oncology@JAMAOnc·
Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy. ja.ma/4d7QXJH
JAMA Oncology tweet media
English
2
17
37
3.7K
GOECP retweetledi
Diego A. Díaz-García
Diego A. Díaz-García@diegoadiazg·
🫁 Adjuvant and Perioperative Immunotherapy. Anti-PD-L1 therapy is moving earlier in the disease course across melanoma, RCC, and NSCLC. Yet consistent OS benefit with adjuvant therapy remains uncertain in several tumors. Emerging strategies: • De-escalation (shorter duration or treatment at recurrence) • Expansion to biomarker-defined high-risk disease • Personalization using ctDNA and other assays Neoadjuvant or perioperative approaches may offer greater benefit than adjuvant therapy in selected settings. 📖 @NatRevClinOncol DOI 👉🏻 doi.org/10.1038/s41571… #CánCare #oncology #immunotherapy #biomarkers #nsclc
Diego A. Díaz-García tweet mediaDiego A. Díaz-García tweet media
English
3
10
37
2.3K
GOECP retweetledi
Adela
Adela@adelapoite·
Stereotactic vs Whole-Brain Radiation for Patients With Brain Metastases - The ASCO Post ascopost.com/news/march-202…
English
1
7
13
598
GOECP retweetledi
PDBrown
PDBrown@PDBrownOnc·
Radiotherapy Review in NEJM: “Underuse and refusal of indicated radiotherapy have been shown to increase cancer-specific mortality and the risk of death in both curative and palliative settings” nejm.org/doi/full/10.10…
English
1
32
100
6.3K
GOECP retweetledi
Joaquín J Cabrera. PhD.
Joaquín J Cabrera. PhD.@JoaquinJCabrera·
Radiotherapy for Unresectable Locally Advanced NSCLC: A Practical Multidisciplinary Approach to Challenging Scenarios From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee jto.org/article/S1556-…
English
1
3
6
480
GOECP retweetledi
Laura Alder, MD
Laura Alder, MD@LauraAlderMD·
Superb talk by @RamalingamMD at #NYLC26 on systemic strategies in stage III CRT NSCLC. How do we improve outcomes? Induction chemo-IO intriguing, especially paired with AI tools to predict pneumonitis. MRD, other bio markers needed to optimize strategies. Lastly, we need more IIT trials for maximal innovation!
Laura Alder, MD tweet mediaLaura Alder, MD tweet mediaLaura Alder, MD tweet media
English
0
8
12
1.4K
GOECP retweetledi
Adela
Adela@adelapoite·
Modern Advancements in Radiation Oncology: What Every Oncologist Should Know | JCO Oncology Practice ascopubs.org/doi/abs/10.120…
English
0
4
11
907
GOECP retweetledi
Advances, an ASTRO Journal
Advances, an ASTRO Journal@Advances_ASTRO·
🌍 Radiation therapy saves lives — but millions still can’t access it. A new global analysis by @RGhalehtaki @NiuSanford & team highlights the gap: 📊 In 2022: ~18.7M cancer diagnoses 🩺 ~11.2M patients needed radiation therapy ⚠️ Only ~68% could access it 🏥 Nearly 8,000 megavoltage RT machines were missing globally And the gap is growing. By 2045: 🔬 ~16.7M patients will need RT ⚙️ ~20,255 additional RT machines will be required Other sobering findings: 🌎 35 countries report zero radiotherapy facilities 🧓 Only ~5–6% of RT machines are <5 years old 📉 Many machines will be >25 years old by 2045 Radiation therapy is essential cancer care. More than half of cancer patients need it at some point. Yet access still depends heavily on geography. ❓So the real question: If we know the need… why are so many patients still waiting? #RadiationOncology #GlobalHealth #CancerCare #HealthEquity #radonc advancesradonc.org/article/S2452-… @ASTRO_org
English
2
19
34
1.9K

Keşfet

@LungCancerEu @IJROBP @myESMO @OncoAlert @Larvol @myesmo @esmo_open @asco